for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Aravive Inc

ARAV.OQ

Latest Trade

6.75USD

Change

0.07(+1.05%)

Volume

415

Today's Range

6.55

 - 

6.75

52 Week Range

3.07

 - 

9.72

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

Aravive Posts Q3 Loss Per Share Of $0.54

Nov 7 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE REPORTS THIRD QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q3 LOSS PER SHARE $0.54.Q3 EARNINGS PER SHARE ESTIMATE $-0.50 -- REFINITIV IBES DATA.AT SEPTEMBER 30, 2019, CASH AND CASH EQUIVALENTS WAS $45.0 MILLION.

Aravive Presents Positive Data From Initial 12 Patients In Phase 1B Portion Of Its Phase 1B/2 Ovarian Cancer Study Of Avb-500 In Late Breaking Oral Presentation At European Society For Medical O

Sept 27 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE PRESENTS POSITIVE DATA FROM INITIAL 12 PATIENTS IN PHASE 1B PORTION OF ITS PHASE 1B/2 OVARIAN CANCER STUDY OF AVB-500 IN LATE BREAKING ORAL PRESENTATION AT EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY CONGRESS IN BARCELONA.ARAVIVE INC - PLANS TO REPORT DETAILED ANALYSIS ONCE DATA FROM INITIAL 30 PATIENTS ON CURRENT 10 MG/KG DOSE MATURE TOWARD END OF YEAR.ARAVIVE INC - INTENDS TO EXPLORE POTENTIAL FOR AN ACCELERATED REGULATORY PATHWAY FOR AVB-500 WITH FDA.ARAVIVE INC - AVB-500 WAS WELL TOLERATED WITH NO DOSE LIMITING TOXICITIES (DLT).ARAVIVE INC - AVB-500 WAS WELL TOLERATED WITH NO DOSE LIMITING TOXICITIES.ARAVIVE INC - PLANS TO INCORPORATE EXPOSURE-RESPONSE INFORMATION INTO THEIR PLANNED STUDIES IN CLEAR CELL RENAL CANCER & RENAL FIBROSIS TRIALS.

Aravive Says Q2 Revenue $3.1 Million

Aug 7 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q2 REVENUE $3.1 MILLION.AT JUNE 30, 2019, CASH AND CASH EQUIVALENTS WERE $48.4 MILLION.QTRLY NET LOSS PER SHARE $0.27.

Aravive Q1 Loss Per Share $0.42

May 8 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q1 LOSS PER SHARE $0.42.CASH AND CASH EQUIVALENTS WERE $55.6 MILLION AS OF MARCH 31, 2019.

Aravive Says Co May Offer Shares Of Common Stock Having Aggregate Offering Price Of Up To $20.25 Million

March 26 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE-MAY OFFER/ SELL SHARES OF COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $20.25 MILLION FROM TIME TO TIME THROUGH PIPER JAFFRAY-SEC FILING.

Aravive Reports Fourth Quarter And Full Year 2018 Financial Results

March 7 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS AND PROVIDES RECENT CORPORATE UPDATES.Q4 LOSS PER SHARE $4.82.CASH AND CASH EQUIVALENTS WERE $57.0 MILLION AS OF DECEMBER 31, 2018.EXPECTS CURRENT CASH AND CASH EQUIVALENTS WILL ENABLE COMPANY TO FUND ITS OPERATING PLANS INTO END OF 2020.QTRLY TOTAL REVENUE $1.4 MILLION VERSUS $40 MILLION.

Aravive Biologics Initiates Phase 1b Portion Of Phase 1b/2 Clinical Trial Of AVB-S6-500 In Platinum-Resistant Recurrent Ovarian Cancer

Dec 11 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE BIOLOGICS INITIATES PHASE 1B PORTION OF PHASE 1B/2 CLINICAL TRIAL OF AVB-S6-500 IN PLATINUM-RESISTANT RECURRENT OVARIAN CANCER.ARAVIVE INC - ANTICIPATE MEASUREMENT OF CIRCULATING FREE GAS6 WILL BE HIGHLY USEFUL AS A BIOMARKER OF DRUG ACTIVITY IN NEW TRIAL.ARAVIVE INC - INITIAL PHASE 1 CLINICAL TRIAL OF AGENT IN HEALTHY VOLUNTEERS SHOWED A FAVORABLE SAFETY AND TOLERABILITY PROFILE.ARAVIVE INC - NO REPORTED SERIOUS ADVERSE EVENTS AND NO ADVERSE EVENTS THAT LIMITED DOSING IN TRIAL.

Aravive Presents Detailed Results Of Phase 1 Clinical Trial Of AVB-S6-500 At The 2018 EORTC-NCI-AACR Symposium

Nov 13 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE PRESENTS DETAILED RESULTS OF PHASE 1 CLINICAL TRIAL OF AVB-S6-500 AT THE 2018 EORTC-NCI-AACR SYMPOSIUM.ARAVIVE INC - PHASE 1 CLINICAL TRIAL IN HEALTHY VOLUNTEERS DEMONSTRATED THAT AVB-S6-500 WAS WELL TOLERATED WITH AN ACCEPTABLE SAFETY PROFILE..ARAVIVE INC - THERE WERE NO SERIOUS ADVERSE EVENTS (AES) AND AVB-S6-500 WAS WELL TOLERATED ACROSS ALL DOSES.

Aravive Qtrly Loss Per Share $1.08

Nov 6 (Reuters) - Aravive Inc <ARAV.O>::ARAVIVE INC QTRLY LOSS PER SHARE $1.08.ARAVIVE INC - CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $62.6 MILLION AS OF SEPTEMBER 30, 2018.

Versartis Q2 Loss Per Share $0.27

Versartis Inc <VSAR.O>::VERSARTIS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND REVIEWS RECENT DEVELOPMENTS.Q2 LOSS PER SHARE $0.27.CASH, CASH EQUIVALENTS, AND SHORT-TERM INVESTMENTS WERE $67.8 MILLION AS OF JUNE 30.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up